Kura Oncology, Inc.
StreetZero Signal 75
About Kura Oncology, Inc.
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Companyโs pipeline consists of small molecule drug candidates that target cancer signaling pathways, including ziftomenib, a once-daily oral drug candidate targeting the menin-KMT2A protein. It is a public company listed on Nasdaq with headquarters in San Diego, California.
LATEST FUNDINGPrivate Placement
$5.0M
Announced 2026-11-18
IN THE NEWS
- ๐ Kura Oncology Announces Oversubscribed $150 Million Private Placement | Kura Oncology, Inc.
- ๐ Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes | Kura Oncology, Inc.
- ๐ Kura Oncology, Inc.
- ๐ Kura Oncology - 2026 Company Profile, Team, Funding, Competitors & Financials - Tracxn
- ๐ Kura Oncology, Inc. (KURA) Stock Analysis & Key Metrics (2026)
EMPLOYEESโ
FOUNDED2014
HQSan Diego, California, United States
Industry
Biotechnology
Tags
BiotechnologyPublic CompanyOncology
Investors
Key highlights
- Raised $150 million in an oversubscribed private placement to fund R&D and operations into 2027.
- Publicly traded on Nasdaq with total historical funding reported between $63.4M and $1.29B across multiple rounds.
- Launched Caspian Therapeutics with $50 million financing focused on menin inhibition for diabetes while retaining substantial ownership.
- Pipeline targets precision oncology with candidates such as ziftomenib for blood cancers and solid tumors.
Ask StreetZero about Kura Oncology, Inc.
Put our AI to work on this deal.
Similar companies
Other Biotechnology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account